  Transforms Wound Care
  In most cases:
  Eliminates Debridement
    Decreases Pain Medications
    Eliminates Antibiotics
    Simplifies Protocol
    Reduces Suffering

Pending Approval

  Benefits Patients with:
     Diabetes
     Paralysis
   Difficult surgical wounds
     Potentially most wounds

Pending Approval - Kenilin Brand Formulations

Kenilin Brand Formulations

The FDA published guidelines in 2004 for a new type of combination drugs (pharmaceutical and botanical). Kenilin is not yet approved but is in the process of running approved studies that permit the first human trials to commence at Rose Medical Center, Denver Colorado and State University of New York (Downstate Medical Center, Brooklyn, NY).

The Name Kenilin

Kenilin is the name of both our medicine and our company, derived from the first names of the original developers of the product, Kenneth Burton MD and Lindsey Berkson MA CNS.